Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article, J Virol Antivir Res Vol: 2 Issue: 3
Enhanced Fitness of Non-Pathogenic SHIV-NM-3rN Over Acute Pathogenic 89.6P in a Dual Infection/Compitition Assay on HSC-F Monkey Derived Cell Line
| Kwofie Theophilus Benjamin1* and Miura Tomoyuki2 |
| 1Department of Clinical Microbiology, School of Medical Sciences, College Health Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana |
| 2Laboratory of Primate Model, Experimental Research Center for Infectious Diseases, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan |
| Corresponding author : Kwofie TB, Ph.D Department of Clinical Microbiology, School of Medical Sciences, College Health Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana Tel: +233 24 4097732; Fax: +233 3220 60302 E-mail: tbenkwofie@yahoo.com |
| Received: August 19, 2013 Accepted: September 11, 2013 Published: September 13, 2013 |
| Citation: Kwofie TB, Miura T (2013) Enhanced Fitness of Non-Pathogenic SHIV-NM-3rN Over Acute Pathogenic 89.6P in a Dual Infection/Compitition Assay on HSC-F Monkey Derived Cell Line. J Virol Antivir Res 2:3. doi:10.4172/2324-8955.1000113 |
Abstract
Enhanced Fitness of Non-Pathogenic SHIV-NM-3rN Over Acute Pathogenic 89.6P in a Dual Infection/Compitition Assay on HSC-F Monkey Derived Cell Line
In a study to use a non-pathogenic Simian/Human Immunodeficiency Virus (SHIV) to overcome pathogenic SHIV in a dual infection/competition assay, two SHIVs, pathogenic 89.6P and non-pathogenic NM-3rN, whose replicative fitness were adjusted to be of equal strength, were mixed together and allowed to compete during many transfers in a monkey-derived cell line HSC-F. This is to identify the conditions under which a nonpathogenic SHIV could out-compete a pathogenic SHIV in order to understand the principles underlying evolution of adaptation and selection and to see if the underlying principle could serve as a guide in the design of a therapeutic Human Immunodeficiency Virus (HIV) vaccine.
